Ovarian Cancer Clinical Trials in Portland

Showing 21-40 of 115 trials

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.

Advanced Solid TumorAdvanced CancerMetastatic Cancer+19 more

MacroGenics250 participantsStarted Mar 2024

Los Angeles, California, United States • Grand Rapids, Michigan, United States • Lake Success, New York, United States +9 more locations

RECRUITING< 1 mile

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAnn Arbor Stage I Lymphoma+59 more

Alliance for Clinical Trials in Oncology2,000 participantsStarted Aug 2022

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +737 more locations

A Study of MGC026 in Participants With Advanced Solid Tumors

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Ovarian Cancer Trials in Other Cities

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Study of AVZO-021 in Patients With Advanced Solid Tumors

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

A Study of PF-06873600 in People With Cancer

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

A Study of PHN-010 in Patients With Advanced Solid Tumors

Nirogacestat in Ovarian Granulosa Cell Tumors

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

A Study of XMT-1660 in Participants With Solid Tumors

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Other Conditions in Portland